The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016

Kevin Winthrop, Vibeke Strand, Désirée Van der Heijde, Philip Mease, Mary K. Crow, Michael Weinblatt, Joan Bathon, Maya H. Buch, Gerd R. Burmester, Maxime Dougados, Jonathan Kay, Xavier Mariette, Ferry C. Breedfeld, Joachim R. Kalden, Josef S. Smolen, Daniel E. Furst

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e.g. Sjögren's, Behçet's, others). In each group, experts were asked to identify unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Needs were prioritised as primary or secondary. Overall, similar primary unmet needs were identified within each disease foci. Within translational science, these included the need for better understanding the heterogeneity within each disease, such that predictive tools for therapeutic response could be developed. Within clinical science and therapeutic trials, the ability to prevent progression to disease onset in those at risk, and the ability to cure disease were identified. A further unmet need was to develop new and accessible therapeutics, as well as to conduct strategic trials of currently approved therapies. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterised, longitudinal cohorts married with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalClinical and Experimental Rheumatology
Volume34
StatePublished - 2016

Fingerprint

Rheumatology
Ankylosing Spondylitis
Therapeutics
Patient-Centered Care
Psoriatic Arthritis
Connective Tissue Diseases
Information Dissemination
Disease Progression
Rheumatoid Arthritis
Morbidity

Keywords

  • Ankylosing spondylitis
  • Lupus
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Spondyloarthritis
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Winthrop, K., Strand, V., Van der Heijde, D., Mease, P., Crow, M. K., Weinblatt, M., ... Furst, D. E. (2016). The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016. Clinical and Experimental Rheumatology, 34, 69-76.

The unmet need in rheumatology : Reports from the Targeted Therapies meeting 2016. / Winthrop, Kevin; Strand, Vibeke; Van der Heijde, Désirée; Mease, Philip; Crow, Mary K.; Weinblatt, Michael; Bathon, Joan; Buch, Maya H.; Burmester, Gerd R.; Dougados, Maxime; Kay, Jonathan; Mariette, Xavier; Breedfeld, Ferry C.; Kalden, Joachim R.; Smolen, Josef S.; Furst, Daniel E.

In: Clinical and Experimental Rheumatology, Vol. 34, 2016, p. 69-76.

Research output: Contribution to journalArticle

Winthrop, K, Strand, V, Van der Heijde, D, Mease, P, Crow, MK, Weinblatt, M, Bathon, J, Buch, MH, Burmester, GR, Dougados, M, Kay, J, Mariette, X, Breedfeld, FC, Kalden, JR, Smolen, JS & Furst, DE 2016, 'The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016', Clinical and Experimental Rheumatology, vol. 34, pp. 69-76.
Winthrop, Kevin ; Strand, Vibeke ; Van der Heijde, Désirée ; Mease, Philip ; Crow, Mary K. ; Weinblatt, Michael ; Bathon, Joan ; Buch, Maya H. ; Burmester, Gerd R. ; Dougados, Maxime ; Kay, Jonathan ; Mariette, Xavier ; Breedfeld, Ferry C. ; Kalden, Joachim R. ; Smolen, Josef S. ; Furst, Daniel E. / The unmet need in rheumatology : Reports from the Targeted Therapies meeting 2016. In: Clinical and Experimental Rheumatology. 2016 ; Vol. 34. pp. 69-76.
@article{c40303b76fdb49aab907de1063026c4a,
title = "The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016",
abstract = "The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e.g. Sj{\"o}gren's, Beh{\cc}et's, others). In each group, experts were asked to identify unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Needs were prioritised as primary or secondary. Overall, similar primary unmet needs were identified within each disease foci. Within translational science, these included the need for better understanding the heterogeneity within each disease, such that predictive tools for therapeutic response could be developed. Within clinical science and therapeutic trials, the ability to prevent progression to disease onset in those at risk, and the ability to cure disease were identified. A further unmet need was to develop new and accessible therapeutics, as well as to conduct strategic trials of currently approved therapies. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterised, longitudinal cohorts married with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.",
keywords = "Ankylosing spondylitis, Lupus, Psoriatic arthritis, Rheumatoid arthritis, Spondyloarthritis, Systemic sclerosis",
author = "Kevin Winthrop and Vibeke Strand and {Van der Heijde}, D{\'e}sir{\'e}e and Philip Mease and Crow, {Mary K.} and Michael Weinblatt and Joan Bathon and Buch, {Maya H.} and Burmester, {Gerd R.} and Maxime Dougados and Jonathan Kay and Xavier Mariette and Breedfeld, {Ferry C.} and Kalden, {Joachim R.} and Smolen, {Josef S.} and Furst, {Daniel E.}",
year = "2016",
language = "English (US)",
volume = "34",
pages = "69--76",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",

}

TY - JOUR

T1 - The unmet need in rheumatology

T2 - Reports from the Targeted Therapies meeting 2016

AU - Winthrop, Kevin

AU - Strand, Vibeke

AU - Van der Heijde, Désirée

AU - Mease, Philip

AU - Crow, Mary K.

AU - Weinblatt, Michael

AU - Bathon, Joan

AU - Buch, Maya H.

AU - Burmester, Gerd R.

AU - Dougados, Maxime

AU - Kay, Jonathan

AU - Mariette, Xavier

AU - Breedfeld, Ferry C.

AU - Kalden, Joachim R.

AU - Smolen, Josef S.

AU - Furst, Daniel E.

PY - 2016

Y1 - 2016

N2 - The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e.g. Sjögren's, Behçet's, others). In each group, experts were asked to identify unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Needs were prioritised as primary or secondary. Overall, similar primary unmet needs were identified within each disease foci. Within translational science, these included the need for better understanding the heterogeneity within each disease, such that predictive tools for therapeutic response could be developed. Within clinical science and therapeutic trials, the ability to prevent progression to disease onset in those at risk, and the ability to cure disease were identified. A further unmet need was to develop new and accessible therapeutics, as well as to conduct strategic trials of currently approved therapies. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterised, longitudinal cohorts married with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.

AB - The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e.g. Sjögren's, Behçet's, others). In each group, experts were asked to identify unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Needs were prioritised as primary or secondary. Overall, similar primary unmet needs were identified within each disease foci. Within translational science, these included the need for better understanding the heterogeneity within each disease, such that predictive tools for therapeutic response could be developed. Within clinical science and therapeutic trials, the ability to prevent progression to disease onset in those at risk, and the ability to cure disease were identified. A further unmet need was to develop new and accessible therapeutics, as well as to conduct strategic trials of currently approved therapies. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterised, longitudinal cohorts married with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.

KW - Ankylosing spondylitis

KW - Lupus

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

KW - Spondyloarthritis

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84984831696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984831696&partnerID=8YFLogxK

M3 - Article

C2 - 27586809

AN - SCOPUS:84984831696

VL - 34

SP - 69

EP - 76

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

ER -